These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 27012422

  • 1. L-Ascorbic acid can abrogate SVCT-2-dependent cetuximab resistance mediated by mutant KRAS in human colon cancer cells.
    Jung SA, Lee DH, Moon JH, Hong SW, Shin JS, Hwang IY, Shin YJ, Kim JH, Gong EY, Kim SM, Lee EY, Lee S, Kim JE, Kim KP, Hong YS, Lee JS, Jin DH, Kim T, Lee WJ.
    Free Radic Biol Med; 2016 Jun; 95():200-8. PubMed ID: 27012422
    [Abstract] [Full Text] [Related]

  • 2. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
    Bäumer S, Bäumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C.
    Clin Cancer Res; 2015 Mar 15; 21(6):1383-94. PubMed ID: 25589625
    [Abstract] [Full Text] [Related]

  • 3. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer.
    Aguilera O, Muñoz-Sagastibelza M, Torrejón B, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, Rodriguez-Remirez M, Zazo S, García E, Fraga M, Rojo F, García-Foncillas J.
    Oncotarget; 2016 Jul 26; 7(30):47954-47965. PubMed ID: 27323830
    [Abstract] [Full Text] [Related]

  • 4. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
    Hong S, Kim S, Kim HY, Kang M, Jang HH, Lee WS.
    Cancer Med; 2016 Feb 26; 5(2):248-55. PubMed ID: 26715098
    [Abstract] [Full Text] [Related]

  • 5. SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment.
    Hong SW, Lee SH, Moon JH, Hwang JJ, Kim DE, Ko E, Kim HS, Cho IJ, Kang JS, Kim DJ, Kim JE, Shin JS, Jung DJ, Jeong YJ, Cho BJ, Kim TW, Lee JS, Kang JS, Hwang YI, Noh DY, Jin DH, Lee WJ.
    Oncogene; 2013 Mar 21; 32(12):1508-17. PubMed ID: 22665050
    [Abstract] [Full Text] [Related]

  • 6. Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer.
    Park HJ, Park JB, Lee SJ, Song M.
    Int J Mol Sci; 2017 Aug 11; 18(8):. PubMed ID: 28800074
    [Abstract] [Full Text] [Related]

  • 7. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 8. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.
    Allen JE, Gallant JN, Dicker DT, Amin S, Irby RB, Sharma AK, El-Deiry WS.
    PLoS One; 2013 Apr 20; 8(3):e59380. PubMed ID: 23555026
    [Abstract] [Full Text] [Related]

  • 9. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells.
    Troiani T, Martinelli E, Napolitano S, Vitagliano D, Ciuffreda LP, Costantino S, Morgillo F, Capasso A, Sforza V, Nappi A, De Palma R, D'Aiuto E, Berrino L, Bianco R, Ciardiello F.
    Clin Cancer Res; 2013 Dec 15; 19(24):6751-65. PubMed ID: 24122793
    [Abstract] [Full Text] [Related]

  • 10. SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts.
    Wang C, Lv H, Yang W, Li T, Fang T, Lv G, Han Q, Dong L, Jiang T, Jiang B, Yang G, Wang H.
    Cancer Lett; 2017 Jul 10; 398():1-11. PubMed ID: 28385602
    [Abstract] [Full Text] [Related]

  • 11. Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.
    Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen M, Wu Q, Xie T, Sui X.
    Theranostics; 2024 Jul 10; 14(14):5443-5460. PubMed ID: 39310106
    [Abstract] [Full Text] [Related]

  • 12. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
    Theranostics; 2020 Jul 10; 10(11):5107-5119. PubMed ID: 32308771
    [Abstract] [Full Text] [Related]

  • 13. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer.
    Cenigaonandia-Campillo A, Serna-Blasco R, Gómez-Ocabo L, Solanes-Casado S, Baños-Herraiz N, Puerto-Nevado LD, Cañas JA, Aceñero MJ, García-Foncillas J, Aguilera Ó.
    Theranostics; 2021 Jul 10; 11(8):3595-3606. PubMed ID: 33664850
    [Abstract] [Full Text] [Related]

  • 14. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression.
    Cho S, Chae JS, Shin H, Shin Y, Song H, Kim Y, Yoo BC, Roh K, Cho S, Kil EJ, Byun HS, Cho SH, Park S, Lee S, Yeom CH.
    Sci Rep; 2018 Jul 27; 8(1):11372. PubMed ID: 30054560
    [Abstract] [Full Text] [Related]

  • 15. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition.
    Troiani T, Napolitano S, Vitagliano D, Morgillo F, Capasso A, Sforza V, Nappi A, Ciardiello D, Ciardiello F, Martinelli E.
    Clin Cancer Res; 2014 Jul 15; 20(14):3775-86. PubMed ID: 24812410
    [Abstract] [Full Text] [Related]

  • 16. A combinatorial strategy for treating KRAS-mutant lung cancer.
    Manchado E, Weissmueller S, Morris JP, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW.
    Nature; 2016 Jun 30; 534(7609):647-51. PubMed ID: 27338794
    [Abstract] [Full Text] [Related]

  • 17. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B, Cuyàs E, Bosch-Barrera J, Massaguer A, de Llorens R, Martin-Castillo B, Brunet J, Salazar R, Menendez JA.
    Oncotarget; 2016 Dec 13; 7(50):82185-82199. PubMed ID: 27636997
    [Abstract] [Full Text] [Related]

  • 18. Digitoxin promotes apoptosis and inhibits proliferation and migration by reducing HIF-1α and STAT3 in KRAS mutant human colon cancer cells.
    Mi C, Cao X, Ma K, Wei M, Xu W, Lin Y, Zhang J, Wang TY.
    Chem Biol Interact; 2022 Jan 05; 351():109729. PubMed ID: 34717917
    [Abstract] [Full Text] [Related]

  • 19. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
    Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, Azad A, Skrinos E, Fluck K, Dobrovic A, Salemi R, Scott AM, Mariadason JM, Tebbutt NC.
    J Clin Oncol; 2012 May 01; 30(13):1505-12. PubMed ID: 22412142
    [Abstract] [Full Text] [Related]

  • 20. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N, Berger AJ, Koenig E, Bannerman B, Garnsey J, Bernard H, Hales P, Maldonado Lopez A, Yang Y, Donelan J, Jordan K, Tirrell S, Stringer B, Xia C, Hather G, Galvin K, Manfredi M, Rhodes N, Amidon B.
    PLoS One; 2015 May 01; 10(12):e0144825. PubMed ID: 26709701
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.